Loading
institutionsInstitution
West German Cancer Center (WTZ), University Hospital Essen
One of Germany's oldest and largest cancer centres, home to the West German Proton Therapy Centre and a leading melanoma and theranostics programme.
Also called: Westdeutsches TumorzentrumUniversitätsklinikum EssenNCT West
Overview
Founded in 1967, the Westdeutsches Tumorzentrum at University Hospital Essen was among the first German Cancer Aid Oncology Centers of Excellence and became a National Center for Tumor Diseases site (NCT West, with Cologne) in 2023. It operates the West German Proton Therapy Centre Essen (WPE), Europe's largest university-based proton facility, treating many paediatric patients. The dermato-oncology group under Dirk Schadendorf has led melanoma immunotherapy and adjuvant trials, and the nuclear medicine department under Ken Herrmann is a high-volume theranostics centre for PSMA and somatostatin-receptor radioligands. Other strengths include sarcoma, uveal melanoma, stem cell transplantation and neuro-oncology.
Location
Essen, DE
Type
cancer center · Universität Duisburg-Essen
Website
Newsweek 2026 oncology rank
Not in top 300 listing used
OnCo score
#53 · 50 points (0 Newsweek + 0 NCI + 50 from 25 linked objects) · ranking
- West German Proton Therapy Centre
- Melanoma and dermato-oncology
- Theranostics and nuclear medicine
- Stem cell transplantation
- NCT West
Dirk Schadendorf
Director WTZ Essen; Director, Department of Dermatology
MelanomaSkin cancerImmunotherapy and targeted therapy
Melanoma expert who directs the West German Cancer Center at University Hospital Essen.
Ken Herrmann
Chair of Nuclear Medicine, University Hospital Essen
TheranosticsPSMA radioligand therapyNuclear medicine
Nuclear medicine leader who co-led VISION and runs one of the world's largest theranostics programmes.
Martin Schuler
Deputy Director WTZ Essen
Thoracic oncologyLung cancerTargeted therapy
Medical oncologist and lung cancer trialist who is Deputy Director of the West German Cancer Center in Essen.
Sebastian Bauer
Medical oncologist, West German Cancer Center, University Hospital Essen
Gastrointestinal stromal tumourSarcomaKinase inhibitors
German sarcoma specialist who was lead author of INTRIGUE, the trial that compared ripretinib with sunitinib as second-line treatment for GIST.
Similar pages
- InstitutionTUM Klinikum rechts der Isar / CCC München
Shares German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Lutetium-177 dotatate, Lutetium-177 vipivotide tetraxetan.
- InstitutionNCT/UCC Dresden, University Hospital Carl Gustav Carus
Shares Deutsche Krebsgesellschaft, German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Proton therapy machines: cyclotrons, synchrotrons and single-room systems.
- InstitutionPostgraduate Institute of Medical Education and Research, Chandigarh
Shares Lutetium-177 dotatate, Lutetium-177 vipivotide tetraxetan, PSMA PET, Radioligand therapy (beta emitters).
- InstitutionUppsala University Hospital / Uppsala University
Shares IBA (Ion Beam Applications), Lutetium-177 dotatate, Radioligand therapy (beta emitters), Proton therapy.
- InstitutionChulabhorn Hospital / Chulabhorn Royal Academy
Shares Lutetium-177 dotatate, Lutetium-177 vipivotide tetraxetan, PSMA PET, Radioligand therapy (beta emitters).
- PersonMichael J. Morris
Shares VISION, Lutetium-177 vipivotide tetraxetan, PSMA PET, Radioligand therapy (beta emitters).
- InstitutionIRCCS Istituto Romagnolo per lo Studio dei Tumori 'Dino Amadori' (IRST)
Shares Lutetium-177 dotatate, Lutetium-177 vipivotide tetraxetan, PSMA PET, Radioligand therapy (beta emitters).
- InstitutionUniversity Hospital Düsseldorf / CIO Düsseldorf
Shares Uniklinik Köln (CIO), Lutetium-177 vipivotide tetraxetan, PSMA PET, Radioligand therapy (beta emitters).
cancers
fronts
technologies
drugs
ApprovedMonoclonal antibody (anti-CTLA-4)
Ipilimumab · Yervoy
ApprovedRadioligand therapy (beta)
Lutetium-177 dotatate · Lutathera
ApprovedRadioligand therapy (beta)
Lutetium-177 vipivotide tetraxetan · Pluvicto
ApprovedMonoclonal antibody (anti-PD-1)
Nivolumab · Opdivo / Opdivo Qvantig (SC)
companies
institutions
trials
people
Open-source projects
All open source in oncology →Open-source projects that this organisation maintains, from OnCo's own catalogue: licence and last activity as the repository reported them on the day of the fetch. Listing is not endorsement; check the licence before reuse and the validation before clinical use.
Vision transformer nuclei detection and classification for whole-slide images from Essen.
398 starslast push 2025-07-23West German Cancer Center (WTZ), University Hospital EssenRepositoryPaper